- Home
- NVX vs PRLD Comparison
NVX vs PRLD Comparison
Compare NVX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- PRLD
- Stock Information
- Founded
- NVX 2012
- PRLD 2016
- Country
- NVX Australia
- PRLD United States
- Employees
- NVX N/A
- PRLD N/A
- Industry
- NVX Industrial Machinery/Components
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- NVX Miscellaneous
- PRLD Health Care
- Exchange
- NVX Nasdaq
- PRLD Nasdaq
- Market Cap
- NVX 208.2M
- PRLD 280.6M
- IPO Year
- NVX N/A
- PRLD 2020
- Fundamental
- Price
- NVX $1.45
- PRLD $4.85
- Analyst Decision
- NVX Strong Buy
- PRLD Hold
- Analyst Count
- NVX 1
- PRLD 3
- Target Price
- NVX $4.00
- PRLD $5.33
- AVG Volume (30 Days)
- NVX 26.0K
- PRLD 242.0K
- Earning Date
- NVX 01-01-0001
- PRLD 10-30-2024
- Dividend Yield
- NVX N/A
- PRLD N/A
- EPS Growth
- NVX N/A
- PRLD N/A
- EPS
- NVX N/A
- PRLD N/A
- Revenue
- NVX $6,875,112.00
- PRLD N/A
- Revenue This Year
- NVX $89.31
- PRLD N/A
- Revenue Next Year
- NVX $429.98
- PRLD N/A
- P/E Ratio
- NVX N/A
- PRLD N/A
- Revenue Growth
- NVX 19.05
- PRLD N/A
- 52 Week Low
- NVX $1.40
- PRLD $1.66
- 52 Week High
- NVX $3.10
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- NVX 37.13
- PRLD 44.87
- Support Level
- NVX $1.54
- PRLD $4.50
- Resistance Level
- NVX $1.60
- PRLD $5.53
- Average True Range (ATR)
- NVX 0.10
- PRLD 0.45
- MACD
- NVX -0.01
- PRLD -0.09
- Stochastic Oscillator
- NVX 9.52
- PRLD 24.22
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.